Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA330383
Max Phase: Preclinical
Molecular Formula: C19H29N3O
Molecular Weight: 315.46
Molecule Type: Small molecule
Associated Items:
ID: ALA330383
Max Phase: Preclinical
Molecular Formula: C19H29N3O
Molecular Weight: 315.46
Molecule Type: Small molecule
Associated Items:
Synonyms (1): 2-Tert-Butylprimaquine
Synonyms from Alternative Forms(1):
Canonical SMILES: COc1cc(NC(C)CCCN)c2nc(C(C)(C)C)ccc2c1
Standard InChI: InChI=1S/C19H29N3O/c1-13(7-6-10-20)21-16-12-15(23-5)11-14-8-9-17(19(2,3)4)22-18(14)16/h8-9,11-13,21H,6-7,10,20H2,1-5H3
Standard InChI Key: IDSOIRUIKYGAHY-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 315.46 | Molecular Weight (Monoisotopic): 315.2311 | AlogP: 4.08 | #Rotatable Bonds: 6 |
Polar Surface Area: 60.17 | Molecular Species: BASE | HBA: 4 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 10.20 | CX LogP: 3.57 | CX LogD: 0.97 |
Aromatic Rings: 2 | Heavy Atoms: 23 | QED Weighted: 0.84 | Np Likeness Score: -0.48 |
1. Jain M, Vangapandu S, Sachdeva S, Singh S, Singh PP, Jena GB, Tikoo K, Ramarao P, Kaul CL, Jain R.. (2004) Discovery of a bulky 2-tert-butyl group containing primaquine analogue that exhibits potent blood-schizontocidal antimalarial activities and complete elimination of methemoglobin toxicity., 47 (2): [PMID:14711300] [10.1021/jm0304562] |
2. Huy NT, Mizunuma K, Kaur K, Nhien NT, Jain M, Uyen DT, Harada S, Jain R, Kamei K.. (2007) 2-tert-butyl-8-quinolinamines exhibit potent blood schizontocidal antimalarial activity via inhibition of heme crystallization., 51 (8): [PMID:17562796] [10.1128/aac.00288-07] |
3. Kaur K, Jain M, Reddy RP, Jain R.. (2010) Quinolines and structurally related heterocycles as antimalarials., 45 (8): [PMID:20466465] [10.1016/j.ejmech.2010.04.011] |
4. Kaur K, Jain M, Khan SI, Jacob MR, Tekwani BL, Singh S, Singh PP, Jain R.. (2011) Synthesis, antiprotozoal, antimicrobial, β-hematin inhibition, cytotoxicity and methemoglobin (MetHb) formation activities of bis(8-aminoquinolines)., 19 (1): [PMID:21172735] [10.1016/j.bmc.2010.11.036] |
5. Kaur K, Jain M, Khan SI, Jacob MR, Tekwani BL, Singh S, Singh PP, Jain R.. (2012) Amino acid, dipeptide and pseudodipeptide conjugates of ring-substituted 8-aminoquinolines: synthesis and evaluation of anti-infective, β-haematin inhibition and cytotoxic activities., 52 [PMID:22483965] [10.1016/j.ejmech.2012.03.019] |
6. Hu YQ, Gao C, Zhang S, Xu L, Xu Z, Feng LS, Wu X, Zhao F.. (2017) Quinoline hybrids and their antiplasmodial and antimalarial activities., 139 [PMID:28800458] [10.1016/j.ejmech.2017.07.061] |
Source(1):